Mohd Qutob, MD
Surgical Oncology · Tulsa, OKNPI 1679952584
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $6,457 of the $10,686 with a category attached, or 60.4%. 16 manufacturers reported payments, led by AbbVie at 44.5% of the total. Reporting peaked in 2023 at $5,015 and has fallen 94.8% since, to $262 in 2025.
Across 88 payments — averaging $121.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Medtronic$2K
- Stryker$1K
- Leica Microsystems Inc.$1K
- Myriad Genetic Laboratories, Inc.$445
- Endomagnetics Ltd$312
- plus $601 from 10 others
What the payments were for
- Consulting fees$4254%
- Travel & lodging$6,45760%
- Food & beverage$3,80436%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 25 | $4,759 |
| Medtronic | 34 | $2,426 |
| Stryker | 11 | $1,072 |
| Leica Microsystems Inc. | 2 | $1,069 |
| Myriad Genetic Laboratories, Inc. | 2 | $445 |
| Endomagnetics Ltd | 3 | $312 |
| Innovation Technologies Inc | 1 | $152 |
| Applied Medical Resources Corporation | 2 | $130 |
| Sirius Medical Systems | 1 | $116 |
| Hologic Sales And Service, LLC | 1 | $48 |
| Avanos Medical | 1 | $32 |
| Merit Medical Systems Inc | 1 | $31 |
| Solventum Corporation | 1 | $29 |
| Cardinal Health 414 LLC | 1 | $26 |
| Pacira Pharmaceuticals Incorporated | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NATRELLE SALINE-FILLED BREAST IMPLANTS$5,397
- STRATTICE RECONSTRUCTIVE TISSUE MATRIX BPS$1,861
- REVOLVE$1,630
- PlasmaBlade$757
- ProGrip$737
- EIKON$641
- myRisk$425
- Magseed$303
- Magtrace$303
- Irrisept$152
- ALLODERM$146
- NEOPROBE$138
- STRATTICE$128
- PINTUITION$116
How this compares
Too few surgical oncology providers in Oklahomato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ibuprofen | 28 | $104 |
| Oxycodone Hcl | 19 | $35 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Tulsa
- John BergquistTulsa$29K
- Edward ChoTulsa$8K
- Laurie FlynnTulsa$3K
- Issac KrileyTulsa$878
- Erica HillTulsa$509
- Huan VuTulsa$345
- Sara SuthersOklahoma City$2K
- Brittany MathiasOklahoma City$1K
- William DooleyOklahoma City$679
- Tara ChandranNorman$648
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.